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794 JOURNAABSTRACT: Although crystal polymorphism of carbamazepine (CBZ), an anticonvul-
sant used to treat epilepsy, has been known for decades, the phenomenon has only
recently been noted for its keto-derivative oxcarbazepine (OCB). Here it is demonstrated
that OCB possesses at least three anhydrous polymorphs. Although all forms are
morphologically similar, making differentiation between crystal modifications by optical
microscopy difficult, powder X-ray diffraction, Raman spectroscopy, and thermomicro-
scopy show distinctive differences. These techniques provide an efficient method of
distinguishing between the three polymorphs. The crystal structure of form II of OCB is
reported for the first time and the structure of form I has been redetermined at low
temperature. Remarkably, both the molecular conformation and crystal packing of form
II are in excellent agreement with the blind prediction made in 2007.  2009 Wiley-Liss,
Inc. and the American Pharmacists Association J Pharm Sci 99:794–803, 2010Keywords: polymorphism; X-ray diffractometry; Raman spectroscopy; crystal struc-
ture; calorimetry (DSC)INTRODUCTION
Polymorphism occurs when a molecule is able
to form multiple crystal structures where the
packing and/or molecular conformation differs
between structures.1 Although this is far from a
universal occurrence in organic compounds,2
crystal polymorphism has considerable technical
importance in industry, especially among phar-
maceuticals, where the presence of different
structures can affect dissolution rate, solubility,
and bioavailability, among other physical char-
acteristics.1 Despite being highly investigated, the
phenomenon of polymorphism continues to pre-
sent new challenges. In molecular solids, hydro-
gen bonding and molecular flexibility are thought
to be factors contributing to increased propensitynce to: Adam J. Matzger (Telephone:
x: 7346158553; E-mail: matzger@umich.edu)
aceutical Sciences, Vol. 99, 794–803 (2010)
, Inc. and the American Pharmacists Association
L OF PHARMACEUTICAL SCIENCES, VOL. 99, NO. 2, FEBUAtowards polymorphism,3 yet predicting the
presence of polymorphic behavior, much less the
structure of the polymorphs, remains an out-
standing challenge. The conditions under which a
crystal is grown clearly affect the crystal structure
in polymorphic systems. Recently, insoluble poly-
mers have been utilized to selectively control the
crystallization of one polymorph over another.4
The use of these polymeric heteronuclei has
become an efficient and effective tool for screening
for polymorphic behavior and the discovery of new
polymorphs4,5 offering the potential to shed light
on this fundamental issue in solid-state chemis-
try. Here we disclose our success in applying
polymer-induced heteronucleation to solid form
discovery for oxcarbazepine.
Carbamazepine (CBZ) (Fig. 1), an important
anticonvulsant, exhibits four structurally char-
acterized polymorphs,6 whereas its dihydro
derivative (10,11-dihydrocarbamazepine) is tri-
morphic.7–9 Its keto-derivative, oxcarbazepine
(OCB) (Fig. 1), also used as an anticonvulsant,RY 2010
Figure 1. Molecular structures of carbamazepine
(left) and oxcarbazepine (right).
CRYSTAL POLYMORPHISM IN A CARBAMAZEPINE DERIVATIVE 795is believed to also be polymorphic and patent
literature claims a total of five polymorphs and a
solvate albeit with levels of characterization
inadequate to prove that these are novel
forms.10,11 The characterization of three anhy-
drous polymorphs is reported herein. The com-
mercially available form I crystallizes in the
monoclinic space group P21/c, with cell constants
of a¼ 5.276(2) Å, b¼ 9.307(4) Å, c¼ 24.841(7) Å,
and b¼ 95.64(2) 8.12 The possibility of other
structures for OCB has been suggested by
computational studies,13 although these have
yet to realize experimental verification. One form
proposed by Cabeza et al. appears to have a
similar powder X-ray diffraction pattern to that of
a form suggested in the patent literature.10,11 The
present study reveals two additional forms of
OCB, including one that matches the prediction of
Cabeza et al., making it, at least, a trimorphic
system. This observation contributes to the
mounting evidence that the basic backbone of
carbamazepine and urea functionality constitute
a polymorphophore.14
The two newly discovered forms of OCB
reported herein, form II and form III, along with
form I have been characterized by Raman spectro-
scopy, differential scanning calorimetry (DSC),
thermomicroscopy, and powder X-ray diffraction
(PXRD). The structure of form I was redetermined
at low temperature. The crystal structure of form
II was solved and found to be in good agreement
with that predicted by Cabeza et al.13EXPERIMENTAL
Materials
Commercial OCB was obtained from Orgamol
(Evionnaz, Switzerland). Toluene (ACS grade)
and methanol (ACS grade) were purchased from
Fisher Scientific (Pittsburgh, PA). Ethylene/vinyl
acetate copolymers and high-density polyethyleneDOI 10.1002/jpswere purchased from Scientific Polymer Products,
Inc. (Ontario, NY).Preparation of OCB Polymorphs
Form I of OCB was obtained directly from the
bottle and from the evaporation of a methanol
solution. Various concentrations were used, with
higher concentrations yielding larger, better
quality crystals. Form II was produced by dissol-
ving 25.0 mg of OCB in 20 mL of toluene and
heating the solution to 1158C until homogeneous.
The solution was then allowed to cool to room
temperature or placed in an ice bath until crystals
were formed. The small needles (in most cases
more powder-like than individual crystals) were
collected after about an hour. Seeding of super-
saturated toluene solutions (2.5 mg/mL) of oxcar-
bazepine at room temperature with form II seeds
consistently yielded bulk form II, whereas the
cooling of the solution alone yielded either form I
or form II. Form III was obtained through the
evaporation of methanol solutions (5 mg/mL) in
the presence of ethylene/vinyl acetate copolymers
or high-density polyethylene at room tempera-
ture.Powder X-Ray Diffraction
PXRD patterns were obtained on a Bruker D8
Advance diffractometer operating at 40 kV and
40 mA with a copper source between 3 and 508 2u
with a step size of 0.0208. The step time for forms I
and II was 5 s and that for form III was 30 s.
Samples were measured directly on a glass slide at
room temperature.Single Crystal X-Ray Diffraction
All measurements were made on a Rigaku R-AXIS
SPIDER diffractometer with an image plate
detector using graphite monochromated Cu-Ka
radiation (1.5406 Å). The data collection was made
at 95 K with the sample mounted on a MiTeGen
MicroMountTM. The structure was solved by
direct methods.15 All calculations were performed
using the CrystalStructure crystallographic soft-
ware package16 except for refinement, which was
performed using SHELXL-97.17JOURNAL OF PHARMACEUTICAL SCIENCES 2010
Table 1. Powder X-Ray Diffraction Peak Positions
and Relative Intensities for the Polymorphs of OCB








7.36 5.0 7.14 55.2 4.95 100.0
796 LUTKER AND MATZGERRaman Spectroscopy
Raman spectra were recorded on a Renishaw
inVia Raman Microscope equipped with a 20
objective and utilizing a 633 nm HeNe laser. The
scan range was 3600–100 cm1 using three scans
of length 60 s per spectrum. A silicon standard was
used to calibrate the instrument.10.36 12.2 11.82 36.6 8.58 74.7
11.96 81.0 14.22 100.0 11.98 27.3
12.10 100.0 17.06 8.5 13.08 89.6
14.43 21.2 17.87 7.3 14.34 15.6
14.54 32.3 18.20 90.0 19.12 12.6
17.39 2.8 18.76 60.1 19.78 34.1
17.84 1.2 19.48 41.9Infrared Spectroscopy
IR spectra were obtained with a Perkin-Elmer
AutoIMAGE FTIR microscopy system in trans-
mission mode using 100 scans per spectrum.19.10 7.7 20.11 1.9
19.27 12.4 20.49 6.6
19.60 6.6 21.18 3.5
20.19 3.7 21.79 42.5
21.28 1.9 22.69 4.2
22.12 3.9 23.40 13.0
23.13 4.7 23.81 6.4
23.24 6.0 24.60 34.7
23.78 17.2 25.42 10.3
24.12 2.8 26.22 4.9
25.36 4.1 26.87 13.2
25.68 5.9 28.00 6.2
25.76 6.3 28.54 2.0
26.28 2.8 29.60 7.6
29.88 5.2 32.90 2.8Thermomicroscopy
A Mettler Toledo FP82HT hot stage using an FP90
control processor was used for thermomicroscopy.
The sample was observed under polarized light
with a Leica DMLP microscope. Samples were
heated from 30 to 2208C at a rate of 58C/min.
Forms II and III were also heated until each fully
transformed and then allowed to cool. The
transformation product was then identified using




44.55 2.8Differential Scanning Calorimetry
DSC was performed on a TA Instruments DSC
Q10. Samples were placed in aluminum hermetic
pans and sealed using a TA Instruments crimper.
The temperature range was 20–3008C with a
heating rate of 108C/min.Figure 2. PXRD patterns of the three polymorphs of
OCB.RESULTS AND DISCUSSION
PXRD
PXRD is a particularly diagnostic way of differ-
entiating between OCB polymorphs. Form I has
characteristic peaks at 2u¼ 10.36, 12.10, and
14.438. Form II has a greater number of intense
peaks than form I and can be distinguished by
those at 2u¼ 11.82, 14.22, 18.20, 21.79, and 24.608.
Form III is easily identifiable by the presence of a
relatively low angle peak at 4.958 2u and other
prominent peaks at 8.58, 11.98, 13.08, and
19.788 2u. Table 1 lists all the peaks and their
relative intensities and Figure 2 presents the
powder patterns.JOURNAL OF PHARMACEUTICAL SCIENCES 2010 DOI 10.1002/jps
CRYSTAL POLYMORPHISM IN A CARBAMAZEPINE DERIVATIVE 797Raman Spectroscopy
Although the Raman spectra of forms I and II are
very similar, they possess several regions where
they can be differentiated. The characteristic
areas where all three polymorphs are easily
discriminated from one another are 100–200,
700–800, 1100–1300, 1500–1700, and 2900–
3400 cm1. For form I, peaks occur at 162.3,
776.7, 1154.3, 1262.4, 1270.6, and 1570.3 cm1.
The corresponding peaks in Form II are 159.5,
778.0, 1152.9, 1259.5, 1272.0, and 1568.9 cm1.
The spectrum for form III differs significantly
from those of forms I and II, making Raman
spectroscopy an efficient method for its identifica-
tion. Form III has corresponding peaks at 155.4,
779.4, 1154.3, 1258.1, 1276.1, and 1594.9 cm1.
Significant differences are also observed in the
hydrogen bonding region between 2900 and
3600 cm1. Here it can be observed that forms I
and II have a similar hydrogen bonding motif
within their crystal structure (see below), whereas
form III is different as evidenced by the missing
peak around 3340 cm1. Forms I and II also each
have a peak around 3470 cm1 that is shifted to
3340 cm1 in the spectrum of form III. A complete
list of peaks is shown in Table 2 and the spectra
are presented in Figure 3.Infrared Spectroscopy
The IR spectra reveal the structural similarities
and disparities between the polymorphs. From the
spectra it can be concluded that the hydrogen
bonding scheme exhibited by forms I and II are
very similar. Form III has a different hydrogen
bonding motif. In forms I and II the hydrogen
bonding motif can be attributed to peaks at about
3471 and 3345 cm1, while in form III a significant
shift and the addition of one peak is observed
(3303, 3353, and 3435 cm1). Other major differ-
ences occur in the carbonyl region that can be
attributed to the hydrogen bonding present in the
crystal structure. In this region the peak that is at
1734 cm1 in form I and 1733 cm1 in form II
disappears entirely from the spectrum of form III.
Another significant dissimilarity is between 900
and 1000 cm1. Form I has peaks at 923, 956, and
985 cm1, while form II has peaks at 922, 959, and
994 cm1 and form III has peaks at 922, 949, 968,
and 997 cm1. The IR spectra are shown in Figure 4
and the peak data are tabulated in Table 3.DOI 10.1002/jpsThermomicroscopy/DSC
The behavior of oxcarbazepine during heating was
observed on a hot stage (58C/min) under crossed
polarizers. No transitions were observed in form I
before it melted. The DSC curve of form I showed
an endotherm (melt/decomposition) with an onset
of 222.68C at a rate of 108C with an enthalpy of
9.64 kcal/mol. Thermomicroscopy proved that
for all polymorphs melting and decomposition
occurred simultaneously and this contributes to
the large melting range measured. During decom-
position the melt turns from colorless to yellow.
The decomposition of oxcarbazepine is dependent
upon the crystal size, with smaller and more
defective crystals decomposing before larger
ones.
A transition between 118 and 1508C was
observed during the heating of form II. The
temperature of this transition is highly dependent
on crystal size and quality, with smaller crystals
having more defects observed to transform before
larger more perfect crystals. The DSC thermo-
gram for form II exhibited an endothermic
transition centered at 127.68C followed immedi-
ately by a broad exothermic transition centered at
165.88C. The approximate enthalpy of the
endotherm is 0.23 kcal/mol while that of the
exotherm was 0.42 kcal/mol. The endotherm is
somewhat less than the predicted energy differ-
ence of 0.61 kcal/mol separating calculated form I
and the next most stable form of Cabeza et al.13
The ensuing melt/decomposition has an onset of
218.28C with an enthalpy of 7.97 kcal/mol. In
order to determine which modification form II
transformed into during heating, a sample was
heated to 1608C and held there for 5 min. The
sample was allowed to cool to room temperature.
Raman microscopy and PXRD was performed on
the product, which proved to be form I.
Form III showed a small transition between 115
and 1258C. The melt occurs between 210 and
2168C. The thermogram of form III shows a large
endothermic transition between 58 and 1508C
with a melt/decomposition onset of 210.08C. The
enthalpy of the transition is 6.23 kcal/mol. To
determine which polymorph form III had trans-
formed into, a sample was heated to 1508C and
held there for 5 min. Upon cooling to room
temperature, the sample was found to be form I
by Raman microscopy. In all of the polymorphs the
melt was concomitant with decomposition. The
DSC thermograms are presented in Figure 5.JOURNAL OF PHARMACEUTICAL SCIENCES 2010
Table 2. Summary of Raman Peak Positions for the Three Polymorphs of OCB
Raman
Shift (cm1) Form I Form II Form III
100–200 3 peaks at 134.9, 162.3, and
186.9
2 peaks at 159.5 with shoulder
at 134.9 and 184.2
2 peaks at 155.4 with shoulder
at 124.0 and 182.8
200–300 1 peak at 266.3 1 peak at 263.5 2 peaks at 259.4 and 269.0
300–400 4 peaks at 310.1, 330.6, 362.1,
and 378.5
3 peaks at 310.1, 329.2, and
360.7 with shoulder at 375.7
3 peaks at 314.2, 330.6, and
362.1 with shoulder at 377.1
400–500 2 peaks at 418.2 with shoulder
at 425.0 and 453.7
2 peaks at 418.2 and 452.4 2 peaks at 429.1 and 457.8
500–600 2 peaks at 515.3 and 553.6 2 peaks at 513.9 and 552.2 3 peaks at 511.2, 555.0, and
598.8
600–700 4 peaks at 612.5 with shoulder
at 598.8, 652.1, 668.6, and
698.7
4 peaks at 612.0 with shoulder
at 601.0, 652.1, 667.2, and
697.3
3 peaks at 622.0, 650.8, and
671.3
700–800 3 peaks at 743.8, 753.4 with
shoulder at 758.9, and 776.7
2 peaks at 743.8 and 778.0 5 peaks at 700.0, 742.4, 756.1,
767.1, and 779.4
800–900 2 peaks at 845.1 and 886.1 3 peaks at 846.4, 882.0, and
888.9
2 peaks at 842.3 and 872.4
900–1000 3 peaks at 924.4, 950.4, and
962.7
3 peaks at 923.1, 950.4, and
966.8
2 peaks at 923.1 and 950.4
1000–1100 2 peaks at 1016.1 with
shoulders at 987.4, 1031.2,
and 1055.8
3 peaks at 1014.7 with
shoulder at 994.2, 1038.0,
and 1055.8
3 peaks at 1016.1 (broad) with
shoulder at 998.3, 1039.4,
and 1053.1
1100–1200 3 peaks at 1107.8, 1154.3 with
shoulder at 1163.8, and
1194.0
3 peaks at 1106.4, 1152.9 with
shoulder at 1165.3, and
1192.6
3 peaks at 1103.7 with
shoulder at 1117.3, 1154.3,
and 1191.3
1200–1300 2 peaks 1237.8 and 1262.4 with
shoulder at 1270.6
3 peaks at 1237.8, 1259.7, and
1272.0
5 peaks at 1244.6, 1258.3,
1276.1, 1287.0, and 1298.0
(broad) with shoulders at
1306.5 and 1317.1
1300–1400 1 peak at 1303.5 (broad) with
shoulder at 1324.0
1 peak at 1300.7 (broad) with
shoulder at 1321.2
0 peaks
1400–1500 3 peaks at 1423.9 with
shoulder at 1406.1, 1451.2,
and 1477.2 with shoulder at
1490.9
3 peaks at 1406.1, 1451.2, and
1477.2 with shoulder at
1491.3
3 peaks at 1419.8, 1451.2, and
1477.2
1500–1600 2 peaks at 1570.3 and 1597.6
with shoulder at 1586.7
2 peaks at 1568.9 and 1597.6
with shoulder at 1587.4
3 peaks at 1523.8, 1571.6 and
1594.9 with shoulder at 16-
07.2
1600–1700 2 peaks at 1653.7 and 1681.1 2 peaks at 1655.1 and 1681.1 2 peaks at 1645.5 and 1675.6
with shoulder at 1683.8
2500–2600 1 peak at 2599.3 1 peak at 2597.9
2800–2900 1 peak at 2820.9 1 peak at 2814.1 1 peak at 2819.6
2900–3000 2 peaks at 2909.9 and 2986.5 2 peaks at 2909.9 and 2975.5
with shoulder at 2986.5
2 peaks at 2911.2 and 2986.5
3000–3100 4 peaks at 3004.3, 3042.6 with
shoulder at 3033.0, and
3076.8 with shoulder at
3063.1
4 peaks at 3005.6, 3018.0,
3042.6, and 3073.6 with
shoulder at 3065.2
4 peaks at 3005.6, 3037.1 with
shoulder at 3039.9, 3061.8,
and 3085.0
3100–3200 1 peak at 3142.5 3 peaks at 3141.1, 3171.2, and
3193.1
3 peaks at 3141.1, 3168.5, and
3187.6
3300–3400 1 peak at 3345.0 1 peak at 3342.3 0 peaks
3400–3500 1 peak at 3473.6 1 peak at 3475.0 1 peak at 3440.8
JOURNAL OF PHARMACEUTICAL SCIENCES 2010 DOI 10.1002/jps
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Figure 3. Raman spectra of the three polymorphs of OCB.
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The crystal structure of form I was re-determined
at low temperature and that of form II was solved
for the first time (Tab. 4, Figs. 6 and 7). The
molecular conformation in forms I and II are
similar. In form I, the azepine ring is in a twist-
boat conformation. The angle between the planes
defined by the benzene rings is 638. The carbox-
amide group is extended above the rest of the
molecule and participates in hydrogen bonding
directed by the carbonyl of the carboxamide group
on one molecule binding with the hydrogen ofFigure 4. Infrared spectra of form
DOI 10.1002/jpsthe NH2 of next molecule creating infinite chains
along the b-axis. The length of the hydrogen bond
ðO   NÞ is 2.77 Å. This differs dramatically from
the anti-hydrogen bonded dimers observed in the
four polymorphs of carbamazepine.6 The second
hydrogen in the carboxamide functionality parti-
cipates in N  H   p bonding with the benzene
ring nearest to it. In addition to hydrogen bonding,
C  H   O interactions are present between the
carbonyl of the azepine ring and a hydrogen on a
benzene ring of a neighboring molecule thus
creating dimers and connecting adjacent hydro-
gen bonded chains. As pointed out previously,13s I, II, and III of oxcarbazepine.
JOURNAL OF PHARMACEUTICAL SCIENCES 2010
Table 3. Summary of IR Peak Positions for the Three Polymorphs of OCB
Wavenumber
(cm1) Form I Form II Form III
700–800 4 peaks at 743, 750, 758, and
771
4 peaks at 742, 751, 758, and
776
4 peaks at 740, 754, 767, and
778
800–900 2 peaks at 846 and 885 with
shoulder at 876
2 peaks at 847 and 888 with
shoulder at 880
2 peaks at 841 and 870
900–1000 3 peaks at 923, 956, and 985 3 peaks at 922, 959 with
shoulder at 948, and 994
4 peaks at 922, 949, 968 with
shoulder at 977, and 997
1000–1100 2 peaks at 1013 and 1027 with
shoulder at 1035
2 peaks at 1012 and 1026 with
shoulder at 1035
3 peaks at 1026 with shoulder
at 1014, 1036, and 1052
1100–1200 3 peaks at 1104 with shoulder
at 1074, 1154, and 1192
3 peaks at 1105 with shoulder
at 1114, 1153, and 1190
1 peak at 1101 (broad) with
shoulder at 1159
1200–1300 3 peaks at 1235, 1269, and 1287
with shoulder at 1304
4 peaks at 1235, 1257, 1270,
and 1287 with shoulder at
1295
5 peaks at 1233, 1241, 1255,
1277, and 1283 with shoulder
at 1293
1300–1400 1 peak at 1313 with shoulder at
1321
1 peak at 1304 2 peaks at 1309 and 1384
(broad) with shoulder at 1417
1400–1500 5 peaks at 1410 with shoulder
at 1372, 1448, 1459, 1474,
and 1489 with shoulder at
1505
4 peaks at 1418 with shoulder
at 1373, 1451 with shoulder
at 1458, 1474, and 1489 with
shoulder at 1505
4 peaks at 1449, 1456, 1474,
and 1489 with shoulder at
1505
1500–1600 3 peaks at 1564, 1586, and 1595 4 peaks at 1539, 1568, 1587,
and 1595
4 peaks at 1540, 1560, 1568,
and 1595
1600–1700 2 peaks at 1652 and 1686 2 peaks at 1652 with shoulder
at 1646 and 1661 and 1687
with shoulder at 1680
3 peaks at 1612, 1641, and 1678
1700–1800 3 peaks at 1716, 1734, and 1771 3 peaks at 1716, 1733, and 1771 3 peaks at 1703, 1771, and 1791
1800–1900 2 peaks at 1843 and 1867 2 peaks at 1843 and 1873 3 peaks at 1813, 1848, and 1875
1900–2000 2 peaks at 1949 and 1974 3 peaks at 1928, 1952, and 1982 3 peaks at 1921, 1953, and 1986
2800–2900 1 peaks at 2849 1 peak at 2855 with shoulder at
2871
2900–3000 3 peaks at 2907, 2949, and 2984 2 peaks at 2917 and 2971 1 peaks at 2956 and 2981
3000–3100 5 peaks at 3001, 3014, 3037,
3070, and 3099
4 peaks at 3002, 3036, 3062,
and 3098
2 peaks at 3037 with shoulder
at 3029 and 3056
3100–3200 2 peaks at 3131 and 3163 1 peak at 3136 1 peaks at 3180 with shoulder
at 3219
3300–3400 1 peak at 3343 with shoulder at
3272
1 peak at 3346 with shoulder at
3272
2 peaks at 3303 and 3353 with
shoulder at 3370
3400–3500 1 peak at 3470 1 peak at 3472 1 peak at 3435
800 LUTKER AND MATZGERform I oxcarbazepine is isostructural to form I of
dihydrocarbamazepine.
The experimental crystal structure of form II is
very similar to the second lowest energy predicted
structure from Cabeza et al.13 The molecular
conformation of form II is related to form I. The
benzene rings are planar and the angle between
the planes is 658. Consistent with the vibrational
spectroscopy, the carboxamide group adopts a
hydrogen bonding scheme similar to that in form I
with infinite chains parallel to the b-axis. The
hydrogen bond ðO   NÞ distance is 2.75 Å. Unlike
form I, the hydrogen of the amide that does notJOURNAL OF PHARMACEUTICAL SCIENCES 2010participate in strong hydrogen bonding forms
N  H   p interactions. A major difference
between the structures of form I and form II is
the nature of the C  H   O interactions. Instead
of the dimers observed in form I, the carbonyl of
the azepine ring interacts with two separate
molecules from an adjacent chain, thus linking
two different chains.
The structure of form III was never determined
due to the small size and poor quality of the
crystals. Crystal size and quality were unable to be
improved upon, despite adjusting crystallization
parameters and attempting seeding. The packingDOI 10.1002/jps
Figure 5. DSC thermographs of the three poly-
morphs of OCB.
Table 4. Cell Parameters for Forms I and II
Form I Form II
Crystal system Monoclinic Monoclinic
Space group P21/c P21
Unit cell
a 5.20194(16) Å 5.1606(2) Å
b 9.2638(3) Å 9.4057(4) Å






Density 1.408 g/cm3 1.372 g/cm3




Goodness of fit 1.017 1.040
Final R indices






CRYSTAL POLYMORPHISM IN A CARBAMAZEPINE DERIVATIVE 801motif observed in forms I and II of oxcarbazepine
differs greatly from that seen in carbamazepine
and some of its other derivatives. One major
difference from carbamazepine is the asymmetry
of azepine ring in OCB. This leads to a greaterFigure 6. Unit cell of form I. (a) View down a
c-axis.
DOI 10.1002/jpspuckering of the azepine ring on one side of the
molecule. This is thought to allow for the
optimization of the hydrogen bonding in a chain
motif.13 All three structures of dihydrocarbama-
zepine also exhibit an analogous hydrogen bond-
ing scheme to OCB, as they all form hydrogen
bonded chains.7–9 The hydrogen bonding in all
four of the carbamazepine polymorphs favor an
anti-dimer motif,6 whereas the structure of
epoxycarbamazepine displays a twisted syn-dimer
configuration.18 In contrast to carbamazepine,
dihydrocarbamazepine form I is almost isostruc--axis, (b) view down b-axis, (c) view down
JOURNAL OF PHARMACEUTICAL SCIENCES 2010
Figure 7. Unit cell of form II. (a) View down a-axis, (b) view down b-axis, (c) view down
c-axis.
802 LUTKER AND MATZGERtural to OCB form I and exhibits a similar
conformation of the azepine ring.13 Hydroxycar-
bamazepine, although similar to OCB and epox-
ycarbamazepine in the fact that it adds an
additional functional group that can participate
in hydrogen bonding, differs from these structures
as it actually hydrogen bonds through the alcohol
in addition the carboxamide functionality and
thus forms neither anti-dimers nor chains.19CONCLUSION
OCB is at minimum trimorphic and two of
these forms are structurally characterized. While
the crystal structure for form III remains elusive,
the presence of this form has been confirmed
through multiple methods. The packing motif for
forms I and II differ from those observed in the
polymorphs of carbamazepine. This shows that
although the basic molecular structure of carba-
mazepine and oxcarbazepine are similar, the
change from a double bond bridge to an alkyl
carbonyl is significant in the packing of the
molecules. Because oxcarbazepine, dihydrocarba-
mazepine, and carbamazepine are polymorphic,
the basic backbone of the molecules should be
considered a polymorphophore.14 Additional work
is needed to verify all of the polymorphic forms
reported in the patent literature.10,11JOURNAL OF PHARMACEUTICAL SCIENCES 2010REFERENCES
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